ZyVersa Therapeutics (ZVSA) said Tuesday that recently published data show inflammasome inhibition may protect pancreatic islet beta cells and reduce progression from obesity to insulin resistance and type 2 diabetes.
ZyVersa's Inflammasome ASC Inhibitor IC 100 aims to reduce obesity-related inflammation by inhibiting inflammasome adaptor protein ASC, the company said.
"This data supports the potential of Inflammasome ASC Inhibitor IC 100, as a key component of obesity care when added to incretins used for weight loss," the company said, adding that it plans to initiate phase 1 trials of IC 100 in mid-2025.
Shares of ZyVersa rose more than 37% in recent trading.
Price: 2.60, Change: +0.77, Percent Change: +42.02
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.